- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03233997
CSD170302: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes
CSD170302: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Colorado
-
Lakewood, Colorado, Forenede Stater, 80228
- Davita Clinical Research
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Able to read, understand, and willing to sign an ICF and complete questionnaires written in English.
- Generally healthy males and females, 21 to 60 years of age, inclusive, at Screening Visit.
Subjects must meet one (a or b) of the following tobacco use conditions:
- Exclusive cigarette smoker who self-reports smoking at least (≥) 10 cigarettes per day for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of the Investigator.
- Dual user of combustible cigarettes and electronic cigarettes (EC) who self-reports:
i. Smoking at least (≥) 10 cigarettes per day for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of the Investigator and ii. Using a nicotine-containing cig-a-like EC or a tank system EC either daily or at least weekly for at least 3 months prior to Screening Visit.
- Willing to be confined overnight and abstain from tobacco- and nicotine- containing product use for 12 hours prior to IP use through Study Discharge.
- Willing to use assigned IP during the study according to protocol.
- Expired breath carbon monoxide (ECO) level is ≥10 parts per million (ppm) at the Screening Visit and Study Day 1.
- Positive urine cotinine test at the Screening Visit and Study Day 1.
- No intent to quit smoking or vaping from the Screening Visit to Study Day 2.
- Females must be willing to use a form of contraception acceptable to the Investigator from the time of signing informed consent until Study Discharge, or be surgically sterile for at least 90 days prior to the Screening Visit.
Exclusion Criteria:
- Presence of clinically significant or unstable/uncontrolled acute or chronic medical conditions at the Screening Visit, as determined by the Investigator, that would preclude a subject from participating safely in the study (e.g., uncontrolled hypertension, diabetes, asthma or other lung disease, cardiac disease, neurological disease or psychiatric disorders) based on safety assessments such as clinical laboratory tests, pregnancy tests, medical history, and physical/oral examinations.
- At risk for heart disease, as determined by the Investigator.
- Systolic blood pressure of > 160 mmHg or a diastolic blood pressure of > 95 mmHg, measured after being seated for 5 minutes.
- Weight of ≤ 110 pounds.
- Poor peripheral venous access.
- Use of medicine for treatment of depression, unless on a stable dose for the past 6 months prior to screening and deemed clinically stable by the PI.
- Current scheduled treatment for asthma within the past consecutive 12 months prior to screening. As needed treatment, such as inhalers, may be included at the PIs discretion pending approval from the medical monitor.
- Any history of cancer, except for primary cancers of skin such as localized basal cell/squamous cell carcinoma that has been surgically and / or cryogenically removed.
- Use of any medication or substance that aids in smoking cessation, including but not limited to any nicotine replacement therapy (NRT) (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within 30 days prior to the Screening Visit.
- History or presence of hemophilia or other bleeding disorders.
- History or presence of clotting disorders with concomitant use of anticoagulants (e.g., clopidogrel [Plavix®], warfarin [Coumadin®, Jantoven®] or aspirin [> 325 mg/day]).
- Participation in another clinical trial within (≤) 30 days prior to the time of consent. The 30-day window for each subject will be derived from the date of the last study event in the previous study to the time of consent of the current study.
- Positive test for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus antibody (anti-HCV).
- Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
- Females ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.
- A positive urine drug screen without disclosure of prescribed corresponding concomitant medication(s) at the Screening Visit or on Study Day 1.
- A positive alcohol breathalyzer result at the Screening Visit or on Study Day 1.
- Employed by a tobacco or nicotine company, the study site, or handles tobacco or nicotine-containing products as part of their job.
- Determined by the Investigator to be inappropriate for the study, including a subject who is unable to communicate or unwilling to cooperate with the clinical staff.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: FT21018 Group
7 day at-home use of electronic cigarette FT21018 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Eksperimentel: FT21033 Group
7 day at-home use of electronic cigarette FT21033 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Eksperimentel: FT21034 Group
7 day at-home use of electronic cigarette FT21034 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Eksperimentel: FT21035 Group
7 day at-home use of electronic cigarette FT21035 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Cmax (maksimal baseline-justeret nikotinplasmakoncentration)
Tidsramme: -5, -0,5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 minutter
|
For at vurdere nikotinoptagelse med starten af en 10-minutters ad libitum undersøgelsesprodukt (IP) brugsperiode.
|
-5, -0,5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 minutter
|
AUCnic0-60
Tidsramme: -5, -0,5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 minutter
|
Område under den baseline-justerede nikotinkoncentration-versus-tid-kurve fra tid nul til 60 minutter efter starten af en 10-minutters ad libitum IP-brugsperiode.
|
-5, -0,5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 minutter
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Samlet set
Tidsramme: 13 minutter
|
Overordnet produkttilfredshed (PL) er et yderligere mål for, hvor meget forsøgspersonen kan lide produktet, og er et udtryk for deres potentielle vilje til at opsøge brugen af produktet igen på et senere tidspunkt; målt 13 minutter efter start af IP-brug.
|
13 minutter
|
Tmax
Tidsramme: -5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
Maximum baseline-adjusted plasma nicotine concentration from time zero to 15 minutes after the start of IP use.
|
-5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
AUCnic0-15
Tidsramme: -5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
Area under the baseline-adjusted nicotine concentration-versus-time curve from time zero to 15 minutes after the start of IP use.
|
-5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Elizabeth Yoon, MSN, FNP-C, Davita Clinical Research
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- CSD170302
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med FT21018
-
RAI Services CompanyVince & Associates Clinical Research, Inc.Afsluttet